ASCO GU 2025: new data confirms triplet therapy benefits, especially with darolutamide
By using advanced statistical methods to adjust for differences in patient populations across 12 clinical trials, researchers found that this triplet therapy consistently outperformed other commonly used treatments, including abiraterone + ADT + docetaxel, abiraterone + ADT, enzalutamide + ADT, apalutamide
By using advanced statistical methods to adjust for differences in patient populations across 12 clinical trials, researchers found that this triplet therapy consistently outperformed other commonly used treatments, including abiraterone + ADT + docetaxel, abiraterone + ADT, enzalutamide + ADT, apalutamide